Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd (TLSA) Option Chain
As of September 22, 2026, Tiziana Life Sciences Ltd is trading at $0.89, a -1.63% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 51.1%. IV Rank is 24%.
Read more
Tracking the TLSA option chain helps you see every strike and expiry on Tiziana Life Sciences Ltd in one view, so you can quickly identify the contracts that fit your thesis and your risk. Tiziana Life Sciences Ltd's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of TLSA options activity at a glance. Use our scanner to monitor the TLSA option chain in real time and filter for the TLSA options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For TLSA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the TLSA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where TLSA stock options are being actively traded and where they are not.
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Tiziana Life Sciences Ltd's full chain across every expiry, highlights the most liquid strikes, and lets you screen TLSA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of TLSA stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile23.41% Subdued
- Market cap (M$)114
- 52 weeks high-62.13%
- 52 weeks low17.11%
- Analyst recommendationStrong Buy
1.00 - Target price$7.98
796.63% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-09-18
- P/E—
- Future P/E—
- EPS (ttm)-0.16
- EPS growth next 5 years-5.34%
As of September 22, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 100.00 | 5 | 0 | 0.10 | 0.00 | — | 0.10 | 2.50 | +180.90 | — | 4.20 | 1.61 | 2.59 | 0 | 0 | 0.00 |
| 100.00 | 0 | 0 | 3.80 | 0.00 | — | 3.80 | 5.00 | +461.80 | 1.60 | 6.50 | 4.11 | -0.06 | 0 | 0 | 0.00 |
| 100.00 | 2 | 0 | 3.80 | 0.00 | — | 3.80 | 7.50 | +742.70 | 4.10 | 9.00 | 6.61 | -0.06 | 0 | 0 | 0.00 |
As of September 22, 2026
Scan the full option chain in one place
Browse the full TLSA option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→